CN101590038A - 一种口服缓释降压组合物 - Google Patents
一种口服缓释降压组合物 Download PDFInfo
- Publication number
- CN101590038A CN101590038A CNA200910012373XA CN200910012373A CN101590038A CN 101590038 A CN101590038 A CN 101590038A CN A200910012373X A CNA200910012373X A CN A200910012373XA CN 200910012373 A CN200910012373 A CN 200910012373A CN 101590038 A CN101590038 A CN 101590038A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutically acceptable
- slow
- bevantolol
- enalapril
- blood pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 29
- 230000001077 hypotensive effect Effects 0.000 title abstract description 7
- 238000013268 sustained release Methods 0.000 title description 7
- 239000012730 sustained-release form Substances 0.000 title description 7
- 208000001953 Hypotension Diseases 0.000 title description 3
- 208000021822 hypotensive Diseases 0.000 title description 3
- HXLAFSUPPDYFEO-UHFFFAOYSA-N bevantolol Chemical compound C1=C(OC)C(OC)=CC=C1CCNCC(O)COC1=CC=CC(C)=C1 HXLAFSUPPDYFEO-UHFFFAOYSA-N 0.000 claims abstract description 53
- 229960003588 bevantolol Drugs 0.000 claims abstract description 52
- 108010061435 Enalapril Proteins 0.000 claims abstract description 47
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims abstract description 41
- 229960000873 enalapril Drugs 0.000 claims abstract description 40
- 230000036772 blood pressure Effects 0.000 claims abstract description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 26
- 239000002775 capsule Substances 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 241000446313 Lamella Species 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 9
- 150000001875 compounds Chemical class 0.000 abstract description 8
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 27
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 24
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 13
- 239000008108 microcrystalline cellulose Substances 0.000 description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 13
- 239000000853 adhesive Substances 0.000 description 12
- 230000001070 adhesive effect Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 235000021355 Stearic acid Nutrition 0.000 description 7
- 229960000309 enalapril maleate Drugs 0.000 description 7
- 239000000945 filler Substances 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 229940032147 starch Drugs 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000008117 stearic acid Substances 0.000 description 7
- 230000003276 anti-hypertensive effect Effects 0.000 description 6
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 6
- -1 hydroxypropyl Chemical group 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 4
- 238000010410 dusting Methods 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000011812 mixed powder Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 108010072661 Angiotensin Amide Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 229940028675 enalapril maleate 2.5 mg Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007948 fast release tablet Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000011450 sequencing therapy Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 238000004457 water analysis Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
活性组分 | 实施例4 | 实施例5 |
依那普利/马来酸依那普利 | 50g | 25g |
微晶纤维素 | 25g | 25g |
低取代羟丙基纤维素 | - | 100g |
聚乙烯吡咯烷酮 | 100g | - |
硬脂酸镁 | 2.5g | 2.5g |
聚乙烯吡咯烷酮 | 5g | 5g |
糖晶种 | 100g | 100g |
成分 | 实施例7 | 实施例8 | 实施例9 |
贝凡洛尔丸芯 | 300g | 300g | 300g |
乙基纤维素 | 80g | - | 100g |
甲基丙烯酸共聚物 | - | 60g | - |
硬脂酸 | 3.0g | - | - |
丙酮 | 300mL | - | 300mL |
异丙醇 | - | 300mL | - |
5min | 10min | 15min | 20min | 30min | 45min | |
胶囊1 | 16.3% | 26.4% | 37.6% | 55.4% | 85.6% | 98.3% |
胶囊2 | 16.7% | 27.6% | 34.6% | 58.2% | 88.5% | 99.2% |
胶囊3 | 15.9% | 26.8% | 33.5% | 57.5% | 86.7% | 98.9% |
1h | 4h | 8h | 12h | |
胶囊1 | 16.3% | 42.4% | 64.6% | 83.75% |
胶囊2 | 16.7% | 47.5% | 69.2% | 89.6% |
胶囊3 | 15.9% | 45.3% | 63.7% | 84.5% |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910012373XA CN101590038B (zh) | 2009-07-06 | 2009-07-06 | 一种口服缓释降压组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910012373XA CN101590038B (zh) | 2009-07-06 | 2009-07-06 | 一种口服缓释降压组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101590038A true CN101590038A (zh) | 2009-12-02 |
CN101590038B CN101590038B (zh) | 2012-02-08 |
Family
ID=41405040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910012373XA Withdrawn - After Issue CN101590038B (zh) | 2009-07-06 | 2009-07-06 | 一种口服缓释降压组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101590038B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104146947A (zh) * | 2014-07-30 | 2014-11-19 | 上海新亚药业闵行有限公司 | 一种抗高血压药物制剂及其制备方法 |
CN112494634A (zh) * | 2020-12-23 | 2021-03-16 | 上海新亚药业闵行有限公司 | 一种稳定的马来酸依那普利口服制剂及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050032879A1 (en) * | 2003-08-07 | 2005-02-10 | Temple Okarter | Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases |
-
2009
- 2009-07-06 CN CN200910012373XA patent/CN101590038B/zh not_active Withdrawn - After Issue
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104146947A (zh) * | 2014-07-30 | 2014-11-19 | 上海新亚药业闵行有限公司 | 一种抗高血压药物制剂及其制备方法 |
CN112494634A (zh) * | 2020-12-23 | 2021-03-16 | 上海新亚药业闵行有限公司 | 一种稳定的马来酸依那普利口服制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101590038B (zh) | 2012-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100341829B1 (ko) | 방출특성이변형된다-유니트투여량조성물 | |
EP4082534A1 (en) | Solid preparation, and preparation method therefor and use thereof | |
CN102008482A (zh) | 一种治疗高血压含缬沙坦的复方制剂 | |
CN1938007A (zh) | 用于口服二甲双胍的控释配方 | |
CN104814923B (zh) | 一种盐酸坦洛新缓释制剂及其制备方法和其应用 | |
CN101990427A (zh) | 米格列奈及二甲双胍的复合制剂及其制造方法 | |
CN106074431A (zh) | 一种富马酸沃诺拉赞制剂及其应用 | |
CN101590038B (zh) | 一种口服缓释降压组合物 | |
CN101371834B (zh) | 含有苯磺酸氨氯地平和坎地沙坦酯的药物组合物和药盒 | |
KR20180087114A (ko) | 모사프리드 또는 이의 염을 포함하는 약제학적 제제 및 이의 제조방법 | |
TWI608849B (zh) | 可調控釋放度之高載藥量之醫藥組合物及其製備方法 | |
CN101411702B (zh) | 盐酸奈福泮萘普生钠复方缓释制剂及其制备方法 | |
CN102552107B (zh) | 含唑吡坦或其盐的双相释放制剂及其制备方法 | |
CN102247366A (zh) | 包括含依那普利或依那普利-酸加成盐的速释微丸和含非洛地平的缓释微丸的药物组合物 | |
CN101214379A (zh) | 一种用于治疗高血压的新组方的缓释制剂及其制备方法 | |
CN109646417A (zh) | 一种曲美他嗪缓释片及其制备方法 | |
CN101849942B (zh) | 治疗高血压的药物组合物 | |
CN103222966A (zh) | 一种含有盐酸芬戈莫德的固体药物组合物及其制备方法 | |
CN101721380A (zh) | 一种制备缓控释制剂的方法 | |
CN101313907A (zh) | 一种用于治疗高血压的药用组合物 | |
EP2883546A1 (en) | New differential-release pharmaceutical composition containing three active principles | |
CN105748422B (zh) | 包含依那普利和非洛地平的药物组合物 | |
CN102349906B (zh) | 阿托伐他汀钙和烟酸组合物及其制备方法 | |
CN100482227C (zh) | 一种复方缓释胶囊及其制备方法 | |
CN112870213B (zh) | 一种用于治疗高血压的药物组合物、固体口服制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Gao Dan Document name: Notification of Passing Examination on Formalities |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200102 Address after: 100124 1605, floor 13, building 3, No. 82, East Fourth Ring Middle Road, Chaoyang District, Beijing Patentee after: Beijing Huayao Kechuang Pharmaceutical Technology Development Co.,Ltd. Address before: 110179 Liaoning province Shenyang Hunnan New Long Street No. 10-1 Co-patentee before: Guan Yi Patentee before: Shenyang Yiling Pharmaceutical Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
AV01 | Patent right actively abandoned |
Granted publication date: 20120208 Effective date of abandoning: 20230727 |
|
AV01 | Patent right actively abandoned |
Granted publication date: 20120208 Effective date of abandoning: 20230727 |
|
AV01 | Patent right actively abandoned | ||
AV01 | Patent right actively abandoned |